S-1/A: Nexalin Technology Eyes $7 Million Capital Injection Through Common Stock Offering

Nexalin Technology is seeking to raise up to $7 million by offering common stock at an assumed price of $2.26 per share, aiming to bolster its financial position and advance its neurostimulation technology.

Summary

• Nexalin Technology is planning a public offering to sell up to $7 million of its common stock at an assumed price of $2.26 per share.
• The offering is on a reasonable best effort basis, with Maxim Group LLC acting as the exclusive placement agent.
• The company intends to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.
• The offering is expected to close no later than two business days following the commencement of sales.
• There is no minimum offering requirement, and the company may sell fewer than all of the shares offered.
• Placement agent fees are estimated at $560,000, assuming all securities are sold.
• The company's common stock is currently listed on the Nasdaq Capital Market under the symbol NXL.
• Nexalin is an emerging growth company and a smaller reporting company, allowing it to comply with certain reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential benefits of the offering and the risks associated with the company and its industry. The sentiment is neutral, reflecting the inherent uncertainties in the company's future prospects.

Positives

• The offering will provide additional capital for working capital, operating expenses, and capital expenditures.
• The company has engaged Maxim Group LLC as the exclusive placement agent.
• Nexalin is an emerging growth company and a smaller reporting company, allowing it to comply with certain reduced public company reporting requirements.

Negatives

• There is no guarantee that the company will sell all of the shares offered.
• The company may receive significantly less in net proceeds than the maximum amount set forth in the prospectus.
• Investors could be in a position where they have invested in the company, but the company has not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds.
• The offering may cause the trading price of the company's common stock to decrease.
• If the company is not able to comply with the applicable continued listing requirements or standards of The Nasdaq Stock Market, Nasdaq could delist the company's common stock.
• The trading price of the company's common stock may be volatile, and investors could lose all or part of their investment.

Risks

• The company may not be able to raise capital when needed, which could force it to delay, reduce, or cease product development programs or commercialization efforts.
• The company depends on the success of its future products, some of which are in clinical development but have not completed advanced clinical trials.
• The company relies on third parties to conduct clinical trials, and those third parties may not perform satisfactorily.
• Even if any of the company's products receives marketing approval, it may fail to achieve the degree of market acceptance necessary for commercial success.
• The company may eventually compete for product sales with other companies, many of which will have greater resources or capabilities.
• Coverage and adequate reimbursement may not be available for the company's current or any future products, which could make it difficult to sell profitably, if approved.
• Product liability lawsuits against the company could cause it to incur substantial liabilities and to limit commercialization of any products that it may develop.
• The company's future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.
• The company expects to expand its development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, it may encounter difficulties in managing its growth, which could disrupt its operations.
• Significant disruptions of the company's information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to the company.
• If the company engages in future acquisitions or strategic collaborations, this may increase its capital requirements, dilute its stockholders, cause it to incur debt or assume contingent liabilities and subject it to other risks.
• The company is subject to the risks of conducting business internationally.
• The medical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of the company's products.
• There may be difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against the company based on foreign laws.
• It may be difficult for overseas regulators to conduct investigations or collect evidence within China.
• The PRC's economic, political and social conditions, as well as governmental policies, could affect the business environment and financial markets in China, and the company's ability to operate its business, maintain its liquidity and keep its access to capital.
• Uncertainties with respect to the PRC legal system could adversely affect the company.
• Restrictions on foreign currency may limit the company's ability to receive and use its joint-venture related revenue effectively.
• Fluctuation in exchange rates could have a negative effect on the company's results of operations and the value of an investment in the company.
• The approval of the CSRC, and other compliance procedures may be required in connection with any offering the company may make and, if required, the company cannot predict whether it will be able to obtain such approval.
• Recent regulatory developments in China may subject the Joint Venture to additional regulatory review and disclosure requirement, expose the Joint Venture to government interference, or otherwise restrict the company's ability to offer securities and raise capital outside China, all of which could materially and adversely affect the company's business and the value of its securities.
• The company may be subject to PRC laws relating to, among others, data security and restrictions over foreign investments in value-added telecommunications services and other industry sectors set out in the Special Administrative Measures (Negative List) for the Access of Foreign Investment (2020 Edition).
• The PRC government has significant influence by enforcing existing rules and regulation, adopting new ones, or changing relevant industrial policies in a manner that may materially increase the company's compliance cost, change relevant industry landscape or otherwise cause significant changes to the Joint Venture's operations in China, which could result in material and adverse changes in the company's operations and cause the value of its securities to significantly decline or be worthless.
• The company may be subject to anti-monopoly concerns as a result of its doing business in China.
• The company may be subject to regulatory and other risks if it were to operate Variable Interest Entities in China
• Substantial uncertainties and restrictions with respect to the political and economic policies of the PRC government and PRC laws and regulations could have a significant impact upon the business that the company may be able to conduct in the PRC and accordingly on the results of its operations and financial condition.
• If the company is unable to obtain and maintain patent protection for its technologies and products, or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize technologies and products similar or identical to ours, and its ability to successfully commercialize its technologies and products may be impaired.
• The company may become involved in lawsuits to protect or enforce its patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.
• Third parties may initiate legal proceedings alleging that the company is infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm its business.
• If the company is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed.
• The company may not be able to protect its intellectual property rights throughout the world.
• Even if the company completes the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent the company or any future collaborators from obtaining approvals for the commercialization of some or all of its products.
• The U.S. FDA, Chinese National Medical Products Administration and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• Even if the company obtains marketing approvals for its products, the terms of approvals and ongoing regulation of its products may limit how it manufactures and markets its products and compliance with such requirements may involve substantial resources, which could materially impair its ability to generate revenue.
• The company's employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
• The company's current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose the company to penalties.
• Recently enacted and future legislation may increase the difficulty and cost for the company and its collaborators to obtain marketing approval of and commercialize its products and affect the prices it may obtain.
• The company's business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which it operates, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit the company's ability to compete in foreign markets and subject it to liability if it violates them.
• If investors purchase shares in this offering, they will suffer immediate and substantial dilution of their investment.
• The company may experience future dilution as a result of future equity offerings or the grant of stock and/or options under out Equity Incentive Plan
• This offering may cause the trading price of the company's common stock to decrease.
• The company has broad discretion in the use of its cash and cash equivalents, including the net proceeds it receives in this offering, and may not use them effectively.
• If the company is not able to comply with the applicable continued listing requirements or standards of The Nasdaq Stock Market, Nasdaq could delist its common stock.
• The trading price of the company's common stock may be volatile, and investors could lose all or part of their investment.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports about the company, its business or its market, its stock price and trading volume could decline.
• The company does not intend to pay cash dividends on its common stock in the foreseeable future.
• Concentration of ownership of the company's common stock among its existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions and matters submitted to stockholders for approval.
• Provisions in the company's corporate charter documents and under Delaware law could make an acquisition of the company, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its current management.
• The company's amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between the company and its stockholders, including claims under the Securities Act and the Exchange Act, which could limit its stockholders ability to obtain a favorable judicial forum for disputes with the company or its directors, officers or employees.
• The company is an emerging growth company and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, its common stock may be less attractive to investors.
• The company has identified certain material weaknesses in its internal controls, which could impair its ability to produce accurate consolidated financial statements on a timely basis.
• From time-to-time, the company may become involved in various legal proceedings that arise in the ordinary course of business or otherwise. Legal proceedings are subject to inherent uncertainties as to timing, outcomes, costs, expenses and time expenditures by its management and others on its behalf.

Future Outlook

The company expects the Joint Venture to begin generating revenue in fiscal year 2025. The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S. and continue to consult with the FDA. The company expects to market its device in the United States as a treatment for depression, assuming successful classification from the FDA.

Industry Context

The document highlights the competitive landscape in the mental health treatment market, noting the shift towards non-pharmacological therapies due to the side effects and limitations of traditional pharmaceuticals. The company believes its technology offers a cost-effective and accessible alternative to traditional treatments.

Comparison to Industry Standards

• The document mentions competition with traditional pharmaceutical therapies and other neurostimulators, including implanted devices.
• It positions Nexalin's products as a cost-effective option compared to existing reimbursed treatments.
• The document references the Harvard American Insomnia Study, indicating the economic burden of insomnia.
• It also cites Research and Markets data projecting the global chronic pain treatment market to reach $151.7 billion in 2030.
• The document mentions the American pharmaceutical industry's embrace of repetitive trans-cranial magnetic stimulation (rTMS).

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may benefit from increased working capital and investment in the company's growth.
• Customers may benefit from the company's continued development of innovative neurostimulation products.
• Suppliers may benefit from increased orders as the company expands its operations.
• Creditors may be impacted by the company's use of proceeds for general corporate purposes.

Next Steps

• File the Prospectus with the Commission pursuant to Rule 424(b).
• Apply to list or quote all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market.
• Take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company's reporting, filing and other obligations under the bylaws or rules of the Trading Market.

Key Dates

Keywords

common stock, public offering, capital raise, neurostimulation, Maxim Group LLC, NXL, FDA, clinical trials, emerging growth company, smaller reporting company, China, intellectual property, regulatory approval, risk factors, financials